BiotechTube

ciclesonide HFA 160 μg

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Perennial Allergic Rhinitis

Conditions

Perennial Allergic Rhinitis

Trial Timeline

Feb 1, 2010 → Nov 1, 2010

NCT ID
NCT01067105

About ciclesonide HFA 160 μg

ciclesonide HFA 160 μg is a phase 3 stage product being developed by Sumitomo Pharma for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01067105. Target conditions include Perennial Allergic Rhinitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01067105Phase 3Completed

Competing Products

20 competing products in Perennial Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
77
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
77
ciclesonide + mometasoneSumitomo PharmaPhase 3
77
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
Budesonide + PlaceboAstraZenecaApproved
85
Ciclesonide + PlaceboAstraZenecaPhase 3
77
CiclesonideAstraZenecaPhase 3
77
CiclesonideAstraZenecaPhase 3
77
Ciclesonide nasal + PlaceboAstraZenecaPhase 3
77
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
85
CiclesonideAstraZenecaPhase 3
77
MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal sprayMerckPhase 3
77
Placebo + Montelukast + Fluticasone propionateMerckApproved
85
montelukast + placeboMerckApproved
85
MK-8237 6 DU + MK-8237 12 DU + PlaceboMerckPhase 1
33
loratadine + loratadine + loratadineMerckApproved
85

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85